SGEN
Seagen Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Market Cap: 43 Billion
Primary Exchange: NASDAQ
Website: seattlegenetics.com
Shares Outstanding: 188 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.23474972990651766
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 646 trading days
From: 2014-02-27 To: 2016-09-20
Lowest Point:
Key events next week - healthcare
via: SeekingAlpha at 2019-06-13 03:28:10:000
Noteworthy events during the week of June 16 - 22 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Merck & Co., Inc., IQVIA Holdings Inc., Healthcare stocks news, , Read more … read more...
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML)
via: Business Wire at 2019-06-12 04:00:00:000
-Data Presentations Highlight Continued Advances in Research for Treating Blood Cancers- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from its ADCETRIS (brentuximab vedotin) clinical development program at the 24 th Annual Congress of the European Hematology As… read more...
Seattle Genetics' Antibody-Drug Conjugate Technology Utilized in Genentech's Polivy, Now Approved by FDA
via: Business Wire at 2019-06-10 08:51:00:000
-Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of Polivy (polatuzumab vedotin-piiq), which is an antibody-drug conjugate (ADC) targeting CD79b that… read more...
Seattle Genetics' Antibody-Drug Conjugate Technology Utilized in Genentech's Polivy, Now Approved by FDA
via: Business Wire at 2019-06-10 08:51:00:000
-Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of Polivy (polatuzumab vedotin-piiq), which is an antibody-drug conjugate (ADC) targeting CD79b that… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|